MYCN is altered in 22.47% of neuroblastoma patients [3].

MYCN is an inclusion criterion in 20 clinical trials for neuroblastoma, of which 16 are open and 4 are closed. Of the trials that contain MYCN status and neuroblastoma as inclusion criteria, 6 are phase 1 (4 open), 3 are phase 1/phase 2 (3 open), 4 are phase 2 (4 open), 3 are phase 3 (3 open), and 4 are no phase specified (2 open) [4].

MYCN is altered in 1.84% of medulloblastoma patients [3].

MYCN is an inclusion criterion in 12 clinical trials for medulloblastoma, of which 12 are open and 0 are closed. Of the trials that contain MYCN status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 5 are phase 1/phase 2 (5 open), 3 are phase 2 (3 open), 1 is phase 4 (1 open), and 1 is no phase specified (1 open) [4].

MYCN is altered in 1.51% of malignant solid tumor patients [3].

MYCN is an inclusion criterion in 4 clinical trials for malignant solid tumor, of which 2 are open and 2 are closed. Of the trials that contain MYCN status and malignant solid tumor as inclusion criteria, 4 are phase 1 (2 open) [4].

MYCN is an inclusion criterion in 4 clinical trials for medulloblastoma, non-WNT/non-SHH, of which 4 are open and 0 are closed. Of the trials that contain MYCN status and medulloblastoma, non-WNT/non-SHH as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 2 (1 open), and 1 is phase 4 (1 open) [4].

MYCN is altered in 5.41% of ependymoma patients [3].

MYCN is an inclusion criterion in 3 clinical trials for ependymoma, of which 3 are open and 0 are closed. Of the trials that contain MYCN status and ependymoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is no phase specified (1 open) [4].

MYCN is altered in 1.01% of soft tissue sarcoma patients [3].

MYCN is an inclusion criterion in 3 clinical trials for soft tissue sarcoma, of which 3 are open and 0 are closed. Of the trials that contain MYCN status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is no phase specified (1 open) [4].

MYCN is an inclusion criterion in 3 clinical trials for desmoplastic small round cell tumor, of which 3 are open and 0 are closed. Of the trials that contain MYCN status and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [4].

MYCN is altered in 3.74% of melanoma patients [3].

MYCN is an inclusion criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain MYCN status and melanoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

MYCN is altered in 1.72% of central nervous system embryonal neoplasm patients [3].

MYCN is an inclusion criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain MYCN status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

MYCN is altered in 2.32% of malignant glioma patients [3].

MYCN is an inclusion criterion in 2 clinical trials for malignant glioma, of which 2 are open and 0 are closed. Of the trials that contain MYCN status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

MYCN is altered in 0.79% of osteosarcoma patients [3].

MYCN is an inclusion criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain MYCN status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

MYCN is an inclusion criterion in 2 clinical trials for atypical teratoid/rhabdoid tumor, of which 2 are open and 0 are closed. Of the trials that contain MYCN status and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

MYCN is an inclusion criterion in 2 clinical trials for central nervous system ganglioneuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain MYCN status and central nervous system ganglioneuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

MYCN is an inclusion criterion in 2 clinical trials for central nervous system neuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain MYCN status and central nervous system neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

MYCN is an inclusion criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain MYCN status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

MYCN is an inclusion criterion in 2 clinical trials for embryonal tumor with multilayered rosettes, C19MC-altered, of which 2 are open and 0 are closed. Of the trials that contain MYCN status and embryonal tumor with multilayered rosettes, C19MC-altered as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

MYCN is an inclusion criterion in 2 clinical trials for large cell/anaplastic medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain MYCN status and large cell/anaplastic medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

MYCN is an inclusion criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain MYCN status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

MYCN is an inclusion criterion in 2 clinical trials for medulloblastoma, SHH-activated, of which 2 are open and 0 are closed. Of the trials that contain MYCN status and medulloblastoma, SHH-activated as inclusion criteria, 2 are phase 1 (2 open) [4].

MYCN is an inclusion criterion in 2 clinical trials for medulloblastoma, WNT-activated, of which 2 are open and 0 are closed. Of the trials that contain MYCN status and medulloblastoma, WNT-activated as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

MYCN is an inclusion criterion in 2 clinical trials for medulloepithelioma, of which 2 are open and 0 are closed. Of the trials that contain MYCN status and medulloepithelioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

MYCN is altered in 15.0% of alveolar rhabdomyosarcoma patients [3].

MYCN is an inclusion criterion in 1 clinical trial for alveolar rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and alveolar rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYCN is altered in 9.64% of kidney Wilms tumor patients [3].

MYCN is an inclusion criterion in 1 clinical trial for kidney Wilms tumor, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and kidney Wilms tumor as inclusion criteria, 1 is no phase specified (1 open) [4].

MYCN is altered in 9.64% of Wilms tumor patients [3].

MYCN is an inclusion criterion in 1 clinical trial for Wilms tumor, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and Wilms tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYCN is altered in 4.35% of high-grade glioma, NOS patients [3].

MYCN is an inclusion criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [4].

MYCN is altered in 3.09% of anaplastic astrocytoma patients [3].

MYCN is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MYCN is altered in 2.24% of glioblastoma patients [3].

MYCN is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MYCN is altered in 2.1% of diffuse glioma patients [3].

MYCN is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

MYCN is altered in 2.02% of glioma patients [3].

MYCN is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and glioma as inclusion criteria, 1 is no phase specified (1 open) [4].

MYCN is altered in 1.2% of retinoblastoma patients [3].

MYCN is an inclusion criterion in 1 clinical trial for retinoblastoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and retinoblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYCN is altered in 1.76% of germ cell tumor patients [3].

MYCN is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and germ cell tumor as inclusion criteria, 1 is no phase specified (1 open) [4].

MYCN is altered in 1.82% of central nervous system neoplasm patients [3].

MYCN is an inclusion criterion in 1 clinical trial for central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and central nervous system neoplasm as inclusion criteria, 1 is no phase specified (1 open) [4].

MYCN is altered in 1.33% of undifferentiated pleomorphic sarcoma patients [3].

MYCN is an inclusion criterion in 1 clinical trial for undifferentiated pleomorphic sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and undifferentiated pleomorphic sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYCN is altered in 1.24% of anaplastic oligodendroglioma patients [3].

MYCN is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [4].

MYCN is altered in 1.16% of diffuse large B-cell lymphoma patients [3].

MYCN is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYCN status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MYCN is altered in 2.18% of small cell lung carcinoma patients [3].

MYCN is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYCN status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

MYCN is altered in 1.13% of mantle cell lymphoma patients [3].

MYCN is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYCN status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MYCN is altered in 0.94% of fibrosarcoma patients [3].

MYCN is an inclusion criterion in 1 clinical trial for fibrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and fibrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYCN is altered in 1.09% of leiomyosarcoma patients [3].

MYCN is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and leiomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYCN is altered in 0.91% of lymphoma patients [3].

MYCN is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MYCN is altered in 0.78% of mature B-cell non-hodgkin lymphoma patients [3].

MYCN is an inclusion criterion in 1 clinical trial for mature B-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYCN status and mature B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MYCN is altered in 0.53% of meningioma patients [3].

MYCN is an inclusion criterion in 1 clinical trial for meningioma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and meningioma as inclusion criteria, 1 is no phase specified (1 open) [4].

MYCN is altered in 0.31% of follicular lymphoma patients [3].

MYCN is an inclusion criterion in 1 clinical trial for follicular lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYCN status and follicular lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MYCN is altered in 0.22% of liposarcoma patients [3].

MYCN is an inclusion criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and liposarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYCN is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, IDH-mutant, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and anaplastic astrocytoma, IDH-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

MYCN is an inclusion criterion in 1 clinical trial for anaplastic ependymoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and anaplastic ependymoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MYCN is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted as inclusion criteria, 1 is phase 1 (1 open) [4].

MYCN is an inclusion criterion in 1 clinical trial for anaplastic pleomorphic xanthoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MYCN is an inclusion criterion in 1 clinical trial for Burkitt lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYCN status and Burkitt lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MYCN is an inclusion criterion in 1 clinical trial for central nervous system lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and central nervous system lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MYCN is an inclusion criterion in 1 clinical trial for childhood central nervous system embryonal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and childhood central nervous system embryonal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYCN is an inclusion criterion in 1 clinical trial for choroid plexus neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and choroid plexus neoplasm as inclusion criteria, 1 is no phase specified (1 open) [4].

MYCN is an inclusion criterion in 1 clinical trial for craniopharyngioma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and craniopharyngioma as inclusion criteria, 1 is no phase specified (1 open) [4].

MYCN is an inclusion criterion in 1 clinical trial for diffuse intrinsic pontine glioma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and diffuse intrinsic pontine glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYCN is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

MYCN is an inclusion criterion in 1 clinical trial for double-hit lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYCN status and double-hit lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MYCN is an inclusion criterion in 1 clinical trial for dysembryoplastic neuroepithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and dysembryoplastic neuroepithelial tumor as inclusion criteria, 1 is no phase specified (1 open) [4].

MYCN is an inclusion criterion in 1 clinical trial for embryonal rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and embryonal rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYCN is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and embryonal tumor with multilayered rosettes, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [4].

MYCN is an inclusion criterion in 1 clinical trial for ependymoma, RELA fusion-positive, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and ependymoma, RELA fusion-positive as inclusion criteria, 1 is phase 1 (1 open) [4].

MYCN is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and Ewing sarcoma as inclusion criteria, 1 is no phase specified (1 open) [4].

MYCN is an inclusion criterion in 1 clinical trial for Ewing sarcoma/peripheral primitive neuroectodermal tumor of bone, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and Ewing sarcoma/peripheral primitive neuroectodermal tumor of bone as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYCN is an inclusion criterion in 1 clinical trial for ganglioneuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and ganglioneuroblastoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MYCN is an inclusion criterion in 1 clinical trial for ganglioneuroblastoma, intermixed, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and ganglioneuroblastoma, intermixed as inclusion criteria, 1 is phase 2 (1 open) [4].

MYCN is an inclusion criterion in 1 clinical trial for ganglioneuroblastoma, nodular, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and ganglioneuroblastoma, nodular as inclusion criteria, 1 is phase 2 (1 open) [4].

MYCN is an inclusion criterion in 1 clinical trial for hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYCN status and hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MYCN is an inclusion criterion in 1 clinical trial for intracranial primitive neuroectodermal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and intracranial primitive neuroectodermal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

MYCN is an inclusion criterion in 1 clinical trial for NUT midline carcinoma of the head and neck, of which 0 are open and 1 is closed. Of the trial that contains MYCN status and NUT midline carcinoma of the head and neck as inclusion criteria, 1 is phase 1 (0 open) [4].

MYCN is an inclusion criterion in 1 clinical trial for neuroectodermal tumor of soft tissue, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and neuroectodermal tumor of soft tissue as inclusion criteria, 1 is no phase specified (1 open) [4].

MYCN is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYCN status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MYCN is an inclusion criterion in 1 clinical trial for pineoblastoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and pineoblastoma as inclusion criteria, 1 is phase 4 (1 open) [4].

MYCN is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYCN is an inclusion criterion in 1 clinical trial for spindle cell sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and spindle cell sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MYCN is an inclusion criterion in 1 clinical trial for synovial sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and synovial sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].